Molecular InSight's presses on with heart imaging agent
This article was originally published in Clinica
Executive Summary
A metabolic imaging agent that could nearly halve the number of patients unnecessarily hospitalised for chest pains is due to complete phase IIb US clinical trials early next year, says the product's developer Molecular Insight Pharmaceuticals. The iodine-133 labelled agent, BMIPP - for use with nuclear imaging equipment, is currently under investigation for the detection of acute coronary ischaemic syndromes (ACS) in the acute care setting.